Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
      Description

      The purpose of this research study is to learn about the effects of the medication ixazomib in participants with scleroderma/systemic sclerosis including its safety and tolerability, its effects on skin, lungs and other organs, and its effects on overall health and quality of life.

      Conditions
      Systemic SclerosisSclerodermaDiffuse Systemic SclerosisDiffuse SclerodermaDiffuse Cutaneous Systemic SclerosisDiffuse Cutaneous SclerodermaProgressive Systemic SclerosisProgressive SclerodermaScleroderma, SystemicScleroderma, DiffuseScleroderma;ProgressiveSystemic Sclerosis, DiffuseSystemic; Sclerosis, ProgressiveScleroderma of LungScleroderma With Pulmonary InvolvementSystemic Sclerosis PulmonarySystemic Sclerosis With Lung InvolvementInterstitial Lung DiseasePulmonary Fibrosis Interstitial
      Talk to us
      COMPLETED
      Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
      Description

      Researchers from the Division of Pulmonary and Critical Care Medicine at University of California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate mofetil (an immunosuppressive medication, trade named CellCept) is safe and effective for preventing the lung damage from scleroderma from getting worse.

      Conditions
      Scleroderma, Systemic
      Talk to us
      RECRUITING
      A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
      Description

      The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has completed enrollment and has been closed for further enrollment. Cohort 2 is enrolling participants.

      Conditions
      Idiopathic Pulmonary FibrosisSystemic Sclerosis With Lung Involvement
      Talk to us